Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA.
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.
Department of Clinical Immunology and Rheumatology/Infectious Diseases, Kyushu University Hospital.
Kentaro
K
To
Noriko
N
Miyake
Yoji
Y
Nagasaki
Nobuyuki
N
Shimono
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood; D003982:Dibekacin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D004696:Endocarditis / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage* / Q000097:blood
D000900:Anti-Bacterial Agents; D003982:Dibekacin; D014640:Vancomycin; C031986:arbekacin